Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Sekar Kathiresan
Person

Sekar Kathiresan

Tracked across 1 events · 12 articles · First seen May 26, 2026 · Last active Jun 07, 2026

Sentiment
70
Attention
8
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
8 70
Tech
VERVE-102 Gene Edit Lowers Cholesterol
Scientists have reported promising results from a groundbreaking gene-editing therapy, VERVE-102, developed by Verve PCSK9-inhibitor gene therapy>>>, a subsidiary of Eli Lilly and Company>>>. This therapy aims to permanently reduce 'bad' cholesterol (LDL cholesterol) after…
Impact: Sekar Kathiresan>>> is a cardiologist who co-founded Verve PCSK9-inhibitor gene therapy>>> and led the research for VERVE-102. His work is central to the development and success of this gene-editing therapy.
May 26, 2026 · 12 articles
NEWSDESK
Track Sekar Kathiresan live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.